Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 11.05.2023
Mexedia S.p.A.
From Telecom to Tech - Driving Innovation with Customer eXperience Platform
as a Service (CXPaaS). Significant boost in sales and profits anticipated.
Mexedia S.p.A. – Società Benefit (Mexedia) is a technology company that
started in the telecom business. Mexedia serves as an intermediary for
wholesale SMS and Voice traffic, fa [ … ]
Thu, 11.05.2023
Mexedia S.p.A.
From Telecom to Tech - Driving Innovation with Customer eXperience Platform
as a Service (CXPaaS). Significant boost in sales and profits anticipated.
Mexedia S.p.A. – Società Benefit (Mexedia) is a technology company that
started in the telecom business. Mexedia serves as an intermediary for
wholesale SMS and Voice traffic, fa [ … ]
Mon, 08.05.2023
First Tin Plc
Strong FY 2022 cash position of £13.8m. Management advancing rapidly both
projects. Possible Germany’s environmental permitting fast-track.
On-track projects. Even with the slight delay for Tellerhäuser, the company
remains on track to deliver DFS studies on both locations for mid-2024 at
latest and is advancing both projec [ … ]
Mon, 08.05.2023
First Tin Plc
Strong FY 2022 cash position of £13.8m. Management advancing rapidly both
projects. Possible Germany’s environmental permitting fast-track.
On-track projects. Even with the slight delay for Tellerhäuser, the company
remains on track to deliver DFS studies on both locations for mid-2024 at
latest and is advancing both projec [ … ]
Mon, 08.05.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 56,00 auf EUR 54,00.
Zusammenfassung:
MPH veröffentlichte vorläufige Kennzahlen für 2022. Wie erwartet stieg der
NAV im Zeitrau [ … ]
Mon, 08.05.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 56,00 auf EUR 54,00.
Zusammenfassung:
MPH veröffentlichte vorläufige Kennzahlen für 2022. Wie erwartet stieg der
NAV im Zeitrau [ … ]
Mon, 08.05.2023
Ikonisys SA
Accelerated business expected
With a strong product pipeline in Circulating Tumor Cells (CTC) based early
cancer detection and treatment monitoring and the integration of AI into
the existing platform, as well as secure funding from Atlas Capital
Markets, we see Ikonisys to be well on track to expand its global reach and
to meet our long-te [ … ]
Mon, 08.05.2023
Ikonisys SA
Accelerated business expected
With a strong product pipeline in Circulating Tumor Cells (CTC) based early
cancer detection and treatment monitoring and the integration of AI into
the existing platform, as well as secure funding from Atlas Capital
Markets, we see Ikonisys to be well on track to expand its global reach and
to meet our long-te [ … ]
Fri, 05.05.2023
Klondike Gold Corp
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von CAD 0,85 auf CAD 0,82.
Zusammenfassung:
Klondike hat den erfolgreichen Abschluss einer Privatplatzierung bekannt
gegeben, die neue Finanzmittel z [ … ]
Fri, 05.05.2023
Klondike Gold Corp
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von CAD 0,85 auf CAD 0,82.
Zusammenfassung:
Klondike hat den erfolgreichen Abschluss einer Privatplatzierung bekannt
gegeben, die neue Finanzmittel z [ … ]